| Christian Martin Itin |
Christian Martin Itin is the founder of Zyomyx, Inc. (founded in 1998). He is currently the Chief Executive Officer at Autolus Ltd. (since 2021) and Autolus Therapeutics Plc (since 2021). He also holds positions as a Non-Executive Director at Kymab Ltd., Director at Kymab Group Ltd., and Director at Autolus Holdings (UK) Ltd. Dr. Itin previously served as the Chairman, CEO & Head-Media Relations at Cytos Biotechnology AG (2012-2016), Chief Executive Officer at Micromet AG (2006), President, Chief Executive Officer & Director at Amgen Rockville, Inc. (2011-2012), and Director at Kuros Biosciences Ltd. (2018-2019). He has also held the role of Non-Executive Director at Zyngenia, Inc. (2013-2014). Dr. Itin obtained a doctorate degree from the University of Basel. |
| David Brochu |
David Brochu is currently the Chief Technical Officer & Senior Vice President at Autolus Therapeutics Plc. He previously worked as the Vice President-Plasma Collection Operations at Grifols Therapeutics, Inc. Mr. Brochu completed his undergraduate degree at Northeastern University. |
| Andrew Paul Mercieca |
Andrew Paul Mercieca is currently the Director at Octant Ltd. and the Chief Accounting Officer & Vice President-Finance at Autolus Therapeutics Plc. Previously, he served as an Independent Director at Orphazyme A in 2022. Mr. Mercieca completed his undergraduate degree at the University of Portsmouth. |
| Alexander Swan |
Alexander Swan has a current job as the Chief Human Resources Officer & Senior VP at Autolus Therapeutics Plc. |
| Brent Rice |
Brent Rice is the founder of Multi Floors LLC. He is currently the Chief Commercial Officer & Senior Vice President at Autolus Therapeutics Plc. In the past, he worked as the Head-Managed Markets at Juno Therapeutics, Inc. Mr. Rice completed his undergraduate degree at the University of California, Los Angeles and earned an MBA from the University of Denver. |
| Christopher Vann |
Christopher Vann is currently the Treasurer & Director at Alliance for Regenerative Medicine since 2023. He is also the Chief Operating Officer & Senior Vice President at Autolus Therapeutics Plc since 2016. Previously, he worked at Roche Holding AG as the Commercial Director from 1994 to 2016. Mr. Vann completed his undergraduate degree at the School of Pharmacy. |
| Michael W. Bonney |
Michael W. Bonney's current jobs include Chairman at Dunad Therapeutics Ltd., Chairman at Autolus Therapeutics Plc, Non-Independent Director at Alnylam Pharmaceuticals, Inc., Director at Gulf of Maine Research Institute, Director at Life Sciences Cares, and Director at X-Biotix Therapeutics, Inc. Former jobs include Chairman at Bates College, Chairman at Gulf of Maine Research Institute, Chairman at Kaleido Biosciences, Inc., Chairman at Magenta Therapeutics, Inc., Chairman at Rare LLC (Virginia), Independent Director at Bristol Myers Squibb Co., Independent Director at Celgene Corp., Independent Director at NPS Pharmaceuticals, Inc., Director at Cubist Pharmaceuticals LLC, Independent Director at Sarepta Therapeutics, Inc., Director at Tekla Capital Management LLC, Director at Pharmaceutical Research & Manufacturers of America, Director at Trius Therapeutics, Inc., Director at Pharmaceutical Manufacturers Association of America, Director-National Business at Zeneca Pharmaceuticals, Independent Director at Global Blood Therapeutics, Inc., Director at Syros Pharmaceuticals, Inc., Director at Revolution Medicines, Inc., Independent Trustee at abrdn Healthcare Investors, Independent Trustee at abrdn Life Sciences Investors, Vice President-Sales & Marketing at Biogen, Inc., Member at Biotechnology Innovation Organization, Trustee at abrdn World Healthcare Fund, Trustee at Beth Israel Deaconess Medical Center, Inc., Partner at Third Rock Ventures LLC, and Independent Trustee at abrdn Healthcare Opportunities Fund. Education history includes an undergraduate degree from Bates College. |
| Martin Patrick Murphy |
Martin Patrick Murphy is the founder and currently holds the position of Chairman at Syncona Partners LLP, which was founded in 2012. He is also the Chief Executive Officer at Syncona LLP, Chairman at Autolus Ltd., Chairman at Blue Earth Diagnostics Ltd., Chairman at Syncona Investment Management Ltd., Chairman at Azeria Therapeutics Ltd., Chairman-Supervisory Board at Anaveon AG, Director at Pulmagen Therapeutics LLP, Director at Biomodal Ltd., Non-Executive Director at Achilles Therapeutics UK Ltd., Non-Executive Director at Autolus Therapeutics Plc, Director at Quell Therapeutics Ltd., Director at Neogene Therapeutics, Inc., Director at Syncona Discovery Ltd., Director at Resolution Therapeutics Ltd., and Director at Clade Therapeutics, Inc. Dr. Murphy's former positions include Chief Executive Officer at Syncona Ltd., Chairman at Serentis Ltd., Chairman at Vantia Ltd., Director at Momenta Pharmaceuticals, Inc., Non-Executive Director at Pulmagen Therapeutics (Synergy) Ltd., Director at Oxxon Therapeutics, Inc., Director at Healthcare Brands International Ltd., Director at PregLem SA, Director at Nxera Pharma UK Ltd., Director at Xention Ltd., Non-Executive Director at Achilles Therapeutics Plc, Principal at 3i Group Plc, Partner at MVM Partners LLP (2002-2012), Member-Healthcare Investment Team at 3i Plc, and Engagement Manager at McKinsey & Co., Inc. (United Kingdom). Dr. Murphy completed his undergraduate studies at the University of Oxford and obtained a doctorate degree from the University of Cambridge in 1994. |
| Robert Dolski |
Robert Dolski's current job is as the Chief Financial Officer & Senior Vice President at Autolus Therapeutics Plc. Formerly, he worked as the Senior Director-Finance at FORUM Pharmaceuticals, Inc. from 2013 to 2016. Prior to that, he was the Vice President-Finance & Treasury at Human Genome Sciences, Inc. from 2007 to 2012. He also served as the Chief Financial Officer at Checkmate Pharmaceuticals, Inc. In addition, Mr. Dolski held the position of Chief Financial & Accounting Officer at Akcea Therapeutics, Inc. in 2020. He was also the Vice President, Head-Financial Planning & Analysis at Moderna, Inc. from 2016 to 2019. Mr. Dolski completed his undergraduate studies at the University of Pennsylvania and obtained an MBA from The Wharton School of the University of Pennsylvania. |
| Martin Pulé |
Martin Pulé is the founder of Autolus Therapeutics Plc, where he currently holds the title of Chief Scientific Officer & Senior Vice President. Autolus Therapeutics Plc was founded in 2014. Dr. Pulé is also the founder of Autolus Ltd. Dr. Pulé's education history includes an undergraduate degree from University College Dublin. |
| Chris Williams |
Chris Williams is currently the Chief Business Development Officer & Senior VP at Autolus Therapeutics Plc. He previously worked as a Non-Executive Director at Autolus Ltd. and as a Director at Orchard Therapeutics (Europe) Ltd. |
| Veronica Hersberger |
Veronica Hersberger is currently the Senior Vice President-Medical Affairs at Autolus Therapeutics Plc since 2023. Previously, she worked as the Chief Medical Officer at Targimmune Therapeutics AG. She obtained a doctorate degree from Universidad de Buenos Aires. |
